Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Year range
1.
Article in English | IMSEAR | ID: sea-110527

ABSTRACT

The chance of incidence of XDR TB is on the rise due to improper use of second line anti-tubercular drugs. XDR-TB is very difficult to treat successfully and is often referred to as "virtually untreatable form of TB". We herein report a case of XDR TB confirmed by bacteriological examination in a WHO recognised laboratory who after 12 months of regular treatment improved both clinically and radiologically with sputum smear conversion. To the best of our knowledge, there has been no previous report of any similar case in literature.


Subject(s)
Adult , Aminosalicylic Acid/therapeutic use , Antitubercular Agents/therapeutic use , Aza Compounds/therapeutic use , Capreomycin/therapeutic use , Clarithromycin/therapeutic use , Clofazimine/therapeutic use , Drug Therapy, Combination , Ethambutol/therapeutic use , Extensively Drug-Resistant Tuberculosis/drug therapy , Humans , India , Injections , Male , Quinolines/therapeutic use , Sputum/microbiology , Treatment Outcome
2.
Enfer. tórax (Lima) ; 50(2): 47-53, mayo-dic. 2006. tab, graf
Article in Spanish | LILACS, LIPECS | ID: lil-538625

ABSTRACT

Objetivos: - Determinar el efecto de la Capreomicina en la depuración de Creatinina Calculada, en pacientes con diagnóstico de Tuberculosis Multidrogoresistente. - Determinar el perfil epidemiológico; la frecuencia de uso de Capreomicina; si existe deterioro de la Depuración de Creatinina Calculada; el uso de fßrmacos AntiTBC como terapia asociada a Capreomicina y establecer la condición de egreso de los pacientes con Tuberculosis MuItidrogoresistente. Método: Se realizó un estudio descriptivo, de tipo retrospectivo en pacientes con Tuberculosis Multidrogoresistente, que fueron atendidos en el Servicio de Neumología del HNGAI entre los a±os 2000-2002, que recibieron la droga Capreomicina como tratamiento Individual izado complementario Resultados: Se revisaron 358 Historias Clínicas de pacientes, que recibieron tratamiento individualizado entre los a±os 2000 al 2002 inclusive, de los cuales 105 pacientes recibieron Capreomicina, 100 pacientes cumplieron con los criterios de inclusión, la cual es la muestra total; el 62 por ciento de pacientes, fueron del género masculino, el 70 por ciento de la población estuvo comprendido entre los 15 a 45 a±os, el 59 por ciento tuvo educación secundaria, el 79 por ciento de pacientes de la serie salió curado. El tiempo de tratamiento promedio de Capreomicina fue de 18.42 meses, el 59 por ciento de la muestra recibió tratamiento entre 12 a 24 meses, el 15 por ciento recibió tratamiento de 24 a 42 meses; las drogas asociadas usadas con mayor frecuencia fueron: Capreomicina (100 por ciento), Cicloserina (100 por ciento), Amoxicilina/Clavulanico (94 por ciento), Ofloxacina (71 por ciento), Pirazinamida (60 por ciento), con un promedio de 4.94 drogas; el 73 por ciento de pacientes de la serie recibieron Dosis de Capreomicina entre 150 a 350 grs como dosis - total, con un valor promedio de la serie de 273.73 grs, El estudio de sensibilidad de las cepas demostró...


Objectives: To determine the effect of Capreomycin in the purification of calculated Creatinine in patients with a diagnose of "Multidrugresistant Tuberculosis". To determine the epidemic profile; the frequency of use of Capreomycin; if deterioration of purification of calculated Creatinine exists; the use of AntiTBC drugs such as therapy associated with Capreomycin and to establish the condition of discharged patients with "Multidrugresistant Tuberculosis". Method: A retrospective descriptive study was carried out in patients with "Multidrugreststant Tuberculosis," that were treated in the Pneumonia Unit of the "HNGAI" between 2000-2002 and who received the Drug Capreomycin as a complementary individualized treatment. Results: 358 Clinical Histories were checked of patients, that received individualized treatment between 2000 and 2002 inclusive; of those, 105 patients received Capreomycin, 100 patients fulfilled the inclusion approaches, which is the total sample; 62 per cent of patients were men, 70 per cent were aged between 15 and 45 years old, 59 per cent had secondary education, 79 per cent of patients came out cured, the average treatment time for Capreomycin was of 18.42 months, 59 per cent of the sample received treatment for between 12 and 24 months, 15 per cent received treatment from 24 to 42 months, the associated drugs used with more frequency...


Subject(s)
Humans , Male , Adolescent , Adult , Female , Middle Aged , Capreomycin , Capreomycin/adverse effects , Capreomycin/therapeutic use , Tuberculosis, Multidrug-Resistant/therapy , Epidemiology, Descriptive , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL